FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2187-2194 November 18, 2004 Number 21 Next

	Full Text PDF PDA Full Text Supplementary Material Perspective by Hamel, M. B. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for a growing proportion of prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs). To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries.

Methods We surveyed state Medicaid agencies to determine whether prescription of coxibs required prior authorization and, if so, the criteria for authorization. For each program, we compared these criteria with evidence-based recommendations for prescribing of coxibs. Using data for all filled prescriptions in 50 state Medicaid programs from 1999 through the end of 2003, we calculated the proportion of defined daily doses of NSAIDs accounted for by coxibs. Time-series analyses were used to measure the changes in prescription patterns after the implementation of each prior-authorization program.

Results By 2001, coxibs accounted for half of all NSAID doses covered by Medicaid. This proportion varied widely according to the state in 2003, from a low of 11 percent to a high of 70 percent of all NSAID doses. Twenty-two states implemented prior-authorization programs for coxibs during the study period. Overall, the implementation of such programs reduced the proportion of NSAID doses made up by coxibs by 15.0 percent (95 percent confidence interval, 10.9 to 19.2 percent), corresponding to a decrease of $10.28 (95 percent confidence interval, $7.56 to $13.00) in spending per NSAID prescription. The effect of such programs was not influenced by the degree to which a prior-authorization program incorporated evidence-based prescribing recommendations.

Conclusions The use of coxibs and spending on NSAIDs varies widely by state and declined substantially after the implementation of prior-authorization programs. Determining whether these reductions are clinically appropriate will have important implications for the development of rational drug-reimbursement policies.

Source Information

From the Divisions of Pharmacoepidemiology and Pharmacoeconomics (M.A.F., S.S., J.A., D.H.S.) and Rheumatology (D.H.S.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Fischer at the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St., Suite 3030, Boston, MA 02120, or at mfischer{at}partners.org.

Full Text of this Article

This article has been cited by other articles:

• West, J. C., Wilk, J. E., Rae, D. S., Muszynski, I. S., Stipec, M. R., Alter, C. L., Sanders, K. E., Crystal, S., Regier, D. A. (2009). Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States. Psychiatr. Serv. 60: 601-610 [Abstract] [Full Text]  
• Jackevicius, C. A., Tu, J. V., Demers, V., Melo, M., Cox, J., Rinfret, S., Kalavrouziotis, D., Johansen, H., Behlouli, H., Newman, A., Pilote, L. (2008). Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel. NEJM 359: 1802-1810 [Abstract] [Full Text]  
• Johnson, T. J., Stahl-Moncada, S. (2008). Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs. Am. J. Public Health 98: 1300-1305 [Abstract] [Full Text]  
• LeLorier, J., Bell, A., Bougher, D. J, Cox, J. L, Turpie, A. G. (2008). Drug Reimbursement Policies in Canada--Need for Improved Access to Critical Therapies. The Annals of Pharmacotherapy 42: 869-873 [Abstract] [Full Text]  
• Law, M. R., Ross-Degnan, D., Soumerai, S. B. (2008). Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements. Psychiatr. Serv. 59: 540-546 [Abstract] [Full Text]  
• Donohue, J. M., Frank, R. G. (2007). Estimating Medicare Part D's Impact on Medication Access Among Dually Eligible Beneficiaries With Mental Disorders. Psychiatr. Serv. 58: 1285-1291 [Abstract] [Full Text]  
• Goldman, D. P., Joyce, G. F., Zheng, Y. (2007). Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health. JAMA 298: 61-69 [Abstract] [Full Text]  
• Polinski, J. M., Wang, P. S., Fischer, M. A. (2007). Medicaid's Prior Authorization Program And Access To Atypical Antipsychotic Medications. Health Aff (Millwood) 26: 750-760 [Abstract] [Full Text]  
• Fischer, M. A., Choudhry, N. K., Winkelmayer, W. C. (2007). Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?. Health Aff (Millwood) 26: 800-807 [Abstract] [Full Text]  
• Huskamp, H. A., Stevenson, D. G., Donohue, J. M., Newhouse, J. P., Keating, N. L. (2007). Economic Grand Rounds: Coverage and Prior Authorization of Psychotropic Drugs Under Medicare Part D. Psychiatr. Serv. 58: 308-310 [Abstract] [Full Text]  
• Fischer, M. A., Servi, A. D., Polinski, J. M., Wang, P. S. (2007). Restrictions on Antidepressant Medications for Children: A Review of Medicaid Policy. Psychiatr. Serv. 58: 135-138 [Abstract] [Full Text]  
• Kesselheim, A. S., Fischer, M. A., Avorn, J. (2006). Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending. Health Aff (Millwood) 25: 1637-1647 [Abstract] [Full Text]  
• Harris, C. L, Raisch, D. W, Abhyankar, U., Marfatia, S., Campbell, H. M, Sather, M. R (2006). GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 40: 1924-1931 [Abstract] [Full Text]  
• Lipton, H. L., Agnew, J. D., Stebbins, M. R., Kuo, A., Dudley, R. A. (2005). Managing the Unmanageable: The Nature and Impact of Drug Risk in Physician Groups. Journal of Health Politics, Policy and Law 30: 719-750 [Abstract]  
• Iadecola, C., Gorelick, P. B. (2005). The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets. Stroke 36: 182-185 [Full Text]